Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …

Background The combination of ibrutinib and venetoclax has been shown to improve
outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …

BCL2 is an apoptosis-inhibitory oncoprotein that also possesses apoptosis-unrelated
activities. Pharmacological BCL2 inhibitors have been developed with the scope of driving …

Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic
leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in …

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) achieves
durable remissions, with flattening of the progression-free survival (PFS) curve in patients …

Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

Background: Small molecules targeting Bruton's tyrosine kinase (BTK) and B-cell lymphoma-
2 have become the standard of care for the treatment of chronic lymphocytic leukemia (CLL) …

Conflict of interest: COI declared-see note COI notes: AWR, MAA, TEL, and VSL are
employees of the Walter and Eliza Hall Institute of Medical Research, which receives …

Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …

Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically
occurs in elderly patients and has a highly variable clinical course. Only patients with active …